428-70-6

Basic information

• Product Name: 1,1,1-trifluoro-2-methyl-3-nitropropan-2-ol
• Synonyms: 1,1,1-trifluoro-2-methyl-3-nitropropan-2-ol
• CAS NO: 428-70-6
• Molecular Formula: C4H6F3NO3
• Molecular Weight: 173.0905496
• Mol File: 428-70-6.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1,1,1-trifluoro-2-methyl-3-nitropropan-2-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 1,1,1-trifluoro-2-methyl-3-nitropropan-2-ol(428-70-6)
• EPA Substance Registry System: 1,1,1-trifluoro-2-methyl-3-nitropropan-2-ol(428-70-6)

Safety Data

• Hazardous Substances Data: 428-70-6(Hazardous Substances Data)

Usage

Physical state

Colorless liquid

Odor

Fruity

Uses

Production of pharmaceuticals, agrochemicals, and other industrial products

Flammability

Highly flammable

Toxicity

Toxic by inhalation, ingestion, and skin contact

Health hazards

Causes irritation to the respiratory system and skin

Chemical class

Nitro compound

Potential hazards

Can release toxic gases when exposed to heat or fire

Precautions

Proper handling and storage required

Upstream product

• 75-52-5 nitromethane 
• 421-50-1 1,1,1-trifluoro-2-propanone 

Downstream Products

• 354-68-7 (±)-3-amino-1,1,1-trifluoro-2-methylpropan-2-ol 

Relevant articles and documents

-

-

Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis

The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.

Pyridine and Pyrazine derivative for the Treatment of CF

The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.